@article{352727938590408f9ef5b179889ab389,
title = "MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer",
abstract = "Ovarian cancer is the most lethal gynecologic malignancy. Recently, several molecularly targeted anticancer agents have been developed for ovarian cancer; however, its prognosis remains extremely poor. The development of molecularly targeted therapy, as well as companion diagnostics, is required to improve outcomes for patients with ovarian cancer. In this study, to identify microRNAs (miRNAs) involved in the progression of ovarian cancer we analyzed serum miRNAs in patients with ovarian cancer using miRNA array and quantitative RT-PCR and examined the anticancer properties of miRNA expression in ovarian cancer cells. In patients with ovarian cancer, high amount of miR-135a-3p in serum samples was significantly associated with favorable clinical prognosis. The amount of miR-135a-3p was significantly decreased in patients with ovarian cancer compared with patients with ovarian cysts or normal ovaries. In SKOV-3 and ES-2 human ovarian cancer cells, enhanced expression of miR-135a-3p induced drug sensitivity to cisplatin and paclitaxel and suppressed cell proliferation and xenograft tumor growth. These findings suggest that miR-135a-3p may be considered as a biomarker and a therapeutic agent in ovarian cancer.",
author = "Satoshi Fukagawa and Kohei Miyata and Fusanori Yotsumoto and Chihiro Kiyoshima and Nam, {Sung Ouk} and Haruchika Anan and Takahiro Katsuda and Daisuke Miyahara and Masaharu Murata and Hiroshi Yagi and Kyoko Shirota and Shin'ichiro Yasunaga and Kiyoko Kato and Shingo Miyamoto",
note = "Funding Information: Funding Information Grant-in-Aid for Young Scientists (B) (227790536) Challenging Exploratory Research (26670731), Scientific Research (B) (26293362), Scientific Research (C) (23592470); Central Research Institute of Fukuoka University (141011); Ministry of Education, Culture, Sports, Science and Technology of Japan; Kakihara Science and Technology Foundation; Princess Takamatsu Cancer Research Fund. This work was supported in part by a Grant-in-Aid for Young Scientists (B) (no. 227790536) Challenging Exploratory Research (no. 26670731), Scientific Research (B) (no. 26293362), Scientific Research (C) (no. 23592470), and funds from the Central Research Institute of Fukuoka University (141011), in addition to The Center for Advanced Molecular Medicine, Fukuoka University from the Ministry of Education, Culture, Sports, Science and Technology (Tokyo, Japan), a Grant-in-Aid from the Kakihara Science and Technology Foundation (Fukuoka, Japan), and the Princess Takamatsu Cancer Research Fund (to S.M.). Publisher Copyright: {\textcopyright} 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.",
year = "2017",
month = may,
doi = "10.1111/cas.13210",
language = "English",
volume = "108",
pages = "886--896",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "5",
}
